Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
FDA Milestone | Soleno Therapeutics secures FDA approval for VYKAT XR, a groundbreaking treatment for Prader-Willi Syndrome, positioning the company as a key player in rare disease therapeutics |
Market Dynamics | Explore the potential of VYKAT XR in a 10,000-patient market, with a strategic focus on 300 top specialists to drive initial adoption and maximize impact |
Financial Outlook | Delve into Soleno's robust financial position, with $285 million in cash reserves and a conservative revenue projection, as analysts set price targets ranging from $67 to $123 |
Competitive Edge | Uncover Soleno's advantages in the PWS treatment landscape, including unmet medical needs, strong clinical data, and a clean FDA label, potentially accelerating VYKAT XR's market penetration |
Metrics to compare | SLNO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLNOPeersSector | |
---|---|---|---|---|
P/E Ratio | −24.0x | −4.0x | −0.5x | |
PEG Ratio | 0.20 | 0.01 | 0.00 | |
Price/Book | 18.1x | 2.5x | 2.6x | |
Price / LTM Sales | 133.1x | 150.6x | 3.3x | |
Upside (Analyst Target) | 49.9% | 137.4% | 43.5% | |
Fair Value Upside | Unlock | 6.5% | 6.8% | Unlock |